NZ255278A - Treatment of sexual dysfunction using an h2 agonist (heterocyclic substituted n-methyl thioethyl guanidine or aminopropylisothiourea derivatives) - Google Patents
Treatment of sexual dysfunction using an h2 agonist (heterocyclic substituted n-methyl thioethyl guanidine or aminopropylisothiourea derivatives)Info
- Publication number
- NZ255278A NZ255278A NZ255278A NZ25527895A NZ255278A NZ 255278 A NZ255278 A NZ 255278A NZ 255278 A NZ255278 A NZ 255278A NZ 25527895 A NZ25527895 A NZ 25527895A NZ 255278 A NZ255278 A NZ 255278A
- Authority
- NZ
- New Zealand
- Prior art keywords
- agonist
- treatment
- pct
- sexual dysfunction
- aminopropylisothiourea
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BR929203277A BR9203277A (pt) | 1992-08-21 | 1992-08-21 | Utilizaccao de drogas eretogenicas e respectivas metodologias de aplicacao |
PCT/BR1993/000027 WO1994004120A2 (en) | 1992-08-21 | 1993-08-18 | Methods of treating sexual dysfunction in animals with and h agonist |
Publications (1)
Publication Number | Publication Date |
---|---|
NZ255278A true NZ255278A (en) | 1999-05-28 |
Family
ID=4054796
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NZ255278A NZ255278A (en) | 1992-08-21 | 1995-02-15 | Treatment of sexual dysfunction using an h2 agonist (heterocyclic substituted n-methyl thioethyl guanidine or aminopropylisothiourea derivatives) |
Country Status (13)
Country | Link |
---|---|
US (1) | US5908853A (xx) |
EP (1) | EP0655914B1 (xx) |
JP (1) | JP2002510277A (xx) |
KR (1) | KR100331754B1 (xx) |
AT (1) | ATE233091T1 (xx) |
BR (1) | BR9203277A (xx) |
CA (1) | CA2142875A1 (xx) |
DE (1) | DE69332713D1 (xx) |
NZ (1) | NZ255278A (xx) |
OA (1) | OA10251A (xx) |
TW (1) | TW418090B (xx) |
WO (1) | WO1994004120A2 (xx) |
ZA (1) | ZA936118B (xx) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050065161A1 (en) * | 1996-02-02 | 2005-03-24 | Nitromed, Inc. | Nitrosated and nitrosylated alpha-adrenergic receptor antagonist compounds, compositions and their uses |
GB9608408D0 (en) * | 1996-04-23 | 1996-06-26 | Adams Michael A | Treatment of erectile dysfunction |
FR2748658B1 (fr) * | 1996-05-15 | 2000-08-18 | Biotec Centre Sa | Utilisation de composes du type "alpha-bloquants" notamment le moxisylyte et/ou ses derives pour le traitement de dysfonctionnements erectiles par voie transmucosale balanique |
GR1002847B (el) * | 1997-05-06 | 1998-01-27 | Χρηση της μισοπροστολης ή/και της μισοπροστολης οξυ για την παρασκευη φαρμακευτικου προιοντος για τη θεραπευτικη αντιμετωπιση των δυσλειτουργιων της στυσεως | |
DE19728103A1 (de) * | 1997-07-02 | 1999-01-07 | Winfried Dr Med Heinicke | Pharmazeutisches Präparat zur Behandlung erektiler Dysfunktion sowie Injektionshilfe zur Injektion des Präparats |
US20020004529A1 (en) * | 1997-10-20 | 2002-01-10 | Gary W. Neal | Methods, compositions, and kits for enhancing female sexual desire and responsiveness |
ZA989513B (en) * | 1997-10-21 | 1999-04-21 | Alcon Lab Inc | Compositions containing histamine H2 agonists and methods of use in treating dry eye |
US6472425B1 (en) | 1997-10-31 | 2002-10-29 | Nitromed, Inc. | Methods for treating female sexual dysfunctions |
GB9802078D0 (en) * | 1998-01-30 | 1998-03-25 | Futura Medical Limited | Preparation for treatment of erectile dysfunction |
FR2774593B1 (fr) * | 1998-02-12 | 2000-05-05 | Philippe Gorny | Obtention d'un medicament destine a combattre les dysfonctions sexuelles feminines |
US6011043A (en) * | 1998-06-19 | 2000-01-04 | Schering Corporation | Combination of phentolamine and apomorphine for the treatment of human sexual function and dysfunction |
GR1003199B (el) | 1998-08-14 | 1999-09-01 | Χρηση της μισοπροστολης ή και της μισοπροστολης οξυ για την παρασκευη φαρμακευτικου προιοντος για τη θεραπευτικη αντιμετωπιση της σεξουαλικης δυσλειτουργιας στις γυναικες | |
FR2786699B1 (fr) * | 1998-12-02 | 2002-10-04 | Philippe Gorny | Medicament destine notamment a prevenir ou traiter les dysfonctions sexuelles |
US6486207B2 (en) * | 1998-12-10 | 2002-11-26 | Nexmed (Holdings), Inc. | Compositions and methods for amelioration of human female sexual dysfunction |
US6825234B2 (en) | 1998-12-10 | 2004-11-30 | Nexmed (Holdings) , Inc. | Compositions and methods for amelioration of human female sexual dysfunction |
US20070191320A1 (en) * | 1998-12-10 | 2007-08-16 | Nexmed Holdings, Inc. | Methods of treatment for female sexual arousal disorder |
CA2408399A1 (en) | 2000-05-09 | 2001-11-15 | Nitromed, Inc. | Infrared thermography and methods of use |
JP2004517036A (ja) * | 2000-05-22 | 2004-06-10 | ラモツト・アツト・テル−アビブ・ユニバーシテイ・リミテツド | 性的障害の治療のためのvip関連ペプチドを含んでなる製薬学的組成物 |
WO2002064212A1 (en) * | 2001-02-13 | 2002-08-22 | Cornell Research Foundation, Inc. | Method and compositions for reducing cardiac dysfunctions with a selective histamine h3 receptor agonist |
WO2003086372A2 (en) * | 2002-04-10 | 2003-10-23 | University Of Florida | Methods of treating medication-, substance-, disease-, and other medical condition-related sexual dysfunction |
US6841574B2 (en) * | 2003-01-03 | 2005-01-11 | Nexmed Holdings, Inc. | Topical stabilized prostaglandin E compound dosage forms |
US7622844B1 (en) * | 2003-12-30 | 2009-11-24 | Hipercon, Llc | Metal fiber brush interface conditioning |
US20060013769A1 (en) * | 2004-07-16 | 2006-01-19 | Stephen Carter | Transdermal drug delivery formulations and method of determining optimal amounts of vasodilators therein |
EP1951186A4 (en) | 2005-10-19 | 2009-11-04 | Menni Menashe Zinger | METHODS FOR TREATING HYPERHIDROSIS |
US20090197892A1 (en) * | 2007-08-21 | 2009-08-06 | Nawaz Ahmad | Anhydrous compositions useful for attaining enhanced sexual wellness |
US8993625B2 (en) | 2009-03-11 | 2015-03-31 | Stable Solutions Llc | Method of mitigating adverse drug events using omega-3 fatty acids as a parenteral therapeutic drug vehicle |
US9034389B2 (en) * | 2009-03-11 | 2015-05-19 | Stable Solutions Llc | Omega-3 enriched fish oil-in-water parenteral nutrition emulsions |
US20140121256A1 (en) * | 2012-10-26 | 2014-05-01 | Beech Tree Labs, Inc. | Method of treating muscular weakness comprising administering a composition comprising an effective amount of histamine and/or serotonin |
CN109219442A (zh) | 2016-04-04 | 2019-01-15 | Omeza有限公司 | 鱼油局部组合物 |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4013659A (en) * | 1973-07-13 | 1977-03-22 | Smith Kline & French Laboratories Limited | Certain n,n'-disubstituted guanidine compounds and their use |
ZA771408B (en) * | 1976-03-29 | 1978-04-26 | Smith Kline French Lab | Pharmaceutical compositions |
JPS52156913A (en) * | 1976-06-21 | 1977-12-27 | Toko Yakuhin Kogyo Kk | Production of injectionable medicine |
US4127118B1 (en) * | 1977-03-16 | 1995-12-19 | Alvaro Latorre | Method of effecting and enhancing an erection |
US4311707A (en) * | 1979-02-12 | 1982-01-19 | American Cyanamid Company | Process for topically producing cutaneous vasodilation for the treatment of vasospastic or ischemic conditions |
US4293562A (en) * | 1979-07-02 | 1981-10-06 | Arnold Ritter | Methods of obtaining anorexic effects using a combination of amphetamines and cimetidine |
US4521421A (en) * | 1983-09-26 | 1985-06-04 | Eli Lilly And Company | Treatment of sexual dysfunction |
DE3413371C1 (de) * | 1984-04-09 | 1986-01-02 | Esselte Pendaflex Corp., Garden City, N.Y. | Etikett |
US4840952A (en) * | 1985-11-01 | 1989-06-20 | Bristol-Myers Company | Method for treatment of male impotence |
US4863911A (en) * | 1986-08-04 | 1989-09-05 | University Of Florida | Method for treating male sexual dysfunction |
EP0266968A3 (en) * | 1986-11-03 | 1988-08-24 | Gérard G. Cohen | Gelled ointment of vasodilating agent |
US4801587A (en) * | 1987-03-02 | 1989-01-31 | Gene Voss | Impotence ointment |
US5256652A (en) * | 1987-11-12 | 1993-10-26 | Pharmedic Co. | Topical compositions and methods for treatment of male impotence |
IT1221826B (it) * | 1988-06-08 | 1990-07-12 | Medico Harvey Srl Centro | Preparato per uso topico per il trattamento terapeutico dell impotentia coeundi |
US5242931A (en) * | 1988-06-09 | 1993-09-07 | Kyowa Hakko Kogyo Co., Ltd. | Tricyclic compounds as TXA2 antagonists |
IL87055A (en) * | 1988-07-08 | 1994-06-24 | Illana Gozes | Conjugates of vasoactive intestinal peptide (vip) and of fragments thereof and pharmaceutical compositions comprising them |
SE463851B (sv) * | 1988-09-02 | 1991-02-04 | Amsu Ltd | Komposition foer behandling av erektil dysfunktion via uretra |
US4931445A (en) * | 1988-10-06 | 1990-06-05 | Irwin Goldstein | Agents for treatment of male impotence |
DE3943519A1 (de) * | 1989-04-27 | 1991-01-17 | Stief Georg | Arzneimittel zur behandlung erektiler dysfunktionen |
US5059603A (en) * | 1989-06-12 | 1991-10-22 | Centuries Laboratories, Inc. | Method and composition for treating impotence |
FR2649613B1 (fr) * | 1989-07-11 | 1991-09-27 | Virag Ronald | Medicament vaso-actif |
IT1252603B (it) * | 1990-04-19 | 1995-06-19 | Giorgio Cavallini | 2,4-diamino-6 piperidino pirimidina-3 ossido topico sul glande nel trattamento delle impotenze erettili |
US5242391A (en) * | 1990-04-25 | 1993-09-07 | Alza Corporation | Urethral insert for treatment of erectile dysfunction |
US5270323A (en) * | 1990-05-31 | 1993-12-14 | Pfizer Inc. | Method of treating impotence |
IT1247678B (it) * | 1990-05-31 | 1994-12-28 | Alberto Reale | Metodo per la cura dell'impotenza erettiva maschile |
GB9012469D0 (en) * | 1990-06-05 | 1990-07-25 | Glaxo Group Ltd | Medicaments |
DK0484581T3 (da) * | 1990-11-08 | 1994-10-24 | Boehringer Mannheim Gmbh | Anvendelse af thromboxan-A2-receptorantagonister til forhindring af degenerative processer i det penile væv |
US5177070A (en) * | 1991-11-15 | 1993-01-05 | Ciba-Geigy Corporation | Method of treating physiologic male erectile impotence |
US5773457A (en) * | 1995-02-15 | 1998-06-30 | Cesar Roberto Dias Nahoum | Compositions |
-
1992
- 1992-08-21 BR BR929203277A patent/BR9203277A/pt not_active Application Discontinuation
-
1993
- 1993-08-18 WO PCT/BR1993/000027 patent/WO1994004120A2/en active IP Right Grant
- 1993-08-18 JP JP50569694A patent/JP2002510277A/ja not_active Ceased
- 1993-08-18 US US08/381,945 patent/US5908853A/en not_active Expired - Fee Related
- 1993-08-18 AT AT93918819T patent/ATE233091T1/de not_active IP Right Cessation
- 1993-08-18 EP EP93918819A patent/EP0655914B1/en not_active Expired - Lifetime
- 1993-08-18 DE DE69332713T patent/DE69332713D1/de not_active Expired - Lifetime
- 1993-08-18 KR KR1019950700672A patent/KR100331754B1/ko not_active IP Right Cessation
- 1993-08-18 CA CA002142875A patent/CA2142875A1/en not_active Abandoned
- 1993-08-20 TW TW082106721A patent/TW418090B/zh not_active IP Right Cessation
- 1993-08-20 ZA ZA936118A patent/ZA936118B/xx unknown
-
1995
- 1995-02-15 NZ NZ255278A patent/NZ255278A/xx unknown
- 1995-02-16 OA OA60612A patent/OA10251A/en unknown
Also Published As
Publication number | Publication date |
---|---|
ATE233091T1 (de) | 2003-03-15 |
WO1994004120A2 (en) | 1994-03-03 |
ZA936118B (en) | 1995-04-20 |
WO1994004120A3 (en) | 1994-05-26 |
AU4937193A (en) | 1994-03-15 |
US5908853A (en) | 1999-06-01 |
AU678996B2 (en) | 1997-06-19 |
EP0655914A1 (en) | 1995-06-07 |
CA2142875A1 (en) | 1994-03-03 |
BR9203277A (pt) | 1994-03-01 |
EP0655914B1 (en) | 2003-02-26 |
DE69332713D1 (de) | 2003-04-03 |
KR950702823A (ko) | 1995-08-23 |
TW418090B (en) | 2001-01-11 |
EP0655914A4 (en) | 1998-04-22 |
KR100331754B1 (ko) | 2002-10-04 |
OA10251A (en) | 1997-10-07 |
JP2002510277A (ja) | 2002-04-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NZ255278A (en) | Treatment of sexual dysfunction using an h2 agonist (heterocyclic substituted n-methyl thioethyl guanidine or aminopropylisothiourea derivatives) | |
PL309596A1 (en) | Application of anticonvulsant agents in treating parkinson disease and parkinsonian syndromes | |
PL309348A1 (en) | Application of an agent called riluzole in therapy of neurological damages caused by or associated with injuries | |
DE69634269D1 (de) | Verfahren zum modulieren der mikrozirkulation | |
GB9317636D0 (en) | Use of dexmedetomidine | |
EA200001010A1 (ru) | Применение дексмедетомидина для седативного воздействия в отделении интенсивной терапии | |
SE9402880D0 (sv) | New peptide derivatives | |
ATE209648T1 (de) | 2,7,-substituierte octahydro-1h-pyrido(1,2- a)pyrazin derivate | |
GR3024854T3 (en) | Drugs for preventing the development of tolerance during treatment with benzodiazepine-receptor-binding substances. | |
NZ503027A (en) | Use of rifamycin derivative for treating mastitis in a domestic animal | |
IL108283A0 (en) | Use of riluzole for promoting restoration following radiation |